
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2491989/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sulfated hyaluronic acid inhibits the hyaluronidase CEMIP and regulates the HA metabolism, proliferation and differentiation of fibroblasts. Matrix Biology, 2022, 109, 173-191.	3.6	10
2	Phenotypic drug discovery: recent successes, lessons learned and new directions. Nature Reviews Drug Discovery, 2022, 21, 899-914.	46.4	81
3	Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part) Tj ETQq1 1	0,784314 1,9	1 rgBT /Ovei
4	Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome. EBioMedicine, 2021, 63, 103162.	6.1	27
5	Glomerular Macrophages in Human Auto- and Allo-Immune Nephritis. Cells, 2021, 10, 603.	4.1	5
6	Neutrophil Extracellular Traps in the Autoimmunity Context. Frontiers in Medicine, 2021, 8, 614829.	2.6	25
7	Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity. Nature Communications, 2021, 12, 3532.	12.8	23
8	Plasma Proteomics of Renal Function: A Transethnic Meta-Analysis and Mendelian Randomization Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 1747-1763.	6.1	16
9	Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nature Communications, 2021, 12, 4662.	12.8	24
10	Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness. Cancer Cell International, 2021, 21, 507.	4.1	8
11	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2021, 32, 3020-3023.	6.1	6
12	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology, 2021, 60, 3176-3188.	1.9	9
13	Neutrophil Extracellular Traps-DNase Balance and Autoimmunity. Cells, 2021, 10, 2667.	4.1	23
14	Anti-alpha enolase multi-antibody specificity in human diseases. Clinical significance and molecular mechanisms. Autoimmunity Reviews, 2021, 20, 102977.	5.8	3
15	Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nature Reviews Drug Discovery, 2020, 19, 93-111.	46.4	190
16	Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance. Frontiers in Oncology, 2020, 10, 1748.	2.8	9
17	Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1762-1776.	4.5	17
18	Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatric Nephrology, 2020, 35, 1437-1444.	1.7	22

#	Article	IF	CITATIONS
19	Discoidin Domain Receptors, DDR1b and DDR2, Promote Tumour Growth within Collagen but DDR1b Suppresses Experimental Lung Metastasis in HT1080 Xenografts. Scientific Reports, 2020, 10, 2309.	3.3	19
20	Clinical trial recommendations for potential Alport syndrome therapies. Kidney International, 2020, 97, 1109-1116.	5.2	7
21	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight, 2020, 5, .	5.0	6
22	Live cell measurements of interaction forces and binding kinetics between Discoidin Domain Receptor 1 (DDR1) and collagen I with atomic force microscopy. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 129402.	2.4	6
23	Deep learning algorithm predicts diabetic retinopathy progression in individual patients. Npj Digital Medicine, 2019, 2, 92.	10.9	178
24	Neutrophil Extracellular Traps protein composition is specific for patients with Lupus nephritis and includes methyl-oxidized αenolase (methionine sulfoxide 93). Scientific Reports, 2019, 9, 7934.	3.3	58
25	Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs. , 2019, 60, 852.		57
26	Machine learning-powered antibiotics phenotypic drug discovery. Scientific Reports, 2019, 9, 5013.	3.3	63
27	DDR1 role in fibrosis and its pharmacological targeting. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 118474.	4.1	57
28	An Update on Antibodies to Necleosome Components as Biomarkers of Sistemic Lupus Erythematosus and of Lupus Flares. International Journal of Molecular Sciences, 2019, 20, 5799.	4.1	23
29	DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome. ACS Chemical Biology, 2019, 14, 37-49.	3.4	84
30	Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime. Journal of Translational Medicine, 2018, 16, 148.	4.4	19
31	Abstract 2135: Complex roles of discoidin domain receptors (DDRs) in tumor growth and experimental metastasis: role of collagen I in DDR-mediated tumor growth. , 2018, , .		Ο
32	Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrology Dialysis Transplantation, 2017, 32, gfw095.	0.7	40
33	Molecular Phenotyping Combines Molecular Information, Biological Relevance, and Patient Data to Improve Productivity of Early Drug Discovery. Cell Chemical Biology, 2017, 24, 624-634.e3.	5.2	32
34	Tubular Cytoplasmic Expression of Zinc Finger Protein SNAI1 in Renal Transplant Biopsies. American Journal of Pathology, 2017, 187, 55-69.	3.8	5
35	BMP7-induced-Pten inhibits Akt and prevents renal fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 3095-3104.	3.8	47
36	Monitoring and manipulating cellular crosstalk during kidney fibrosis inside a 3D in vitro co-culture. Scientific Reports, 2017, 7, 14490.	3.3	15

#	Article	IF	CITATIONS
37	Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 2017, 16, 531-543.	46.4	607
38	Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10666-10671.	7.1	54
39	Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Research, 2016, 76, 1560-1568.	0.9	15
40	Abstract 1290: Actinomycin D enhanced immunotoxin RG7787 killing of cancer cells. , 2016, , .		0
41	Abstract 743: Tyrosine kinase discoidin domain receptor-1 (DDR1) regulates cytotoxicity of recombinant immunotoxin for cancer therapy. , 2016, , .		0
42	Stable incorporation of αâ€smooth muscle actin into stress fibers is dependent on specific tropomyosin isoforms. Cytoskeleton, 2015, 72, 257-267.	2.0	29
43	New renal drug development to face chronic renal disease. Expert Opinion on Drug Discovery, 2014, 9, 1471-1485.	5.0	8
44	Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. Journal of Proteomics, 2013, 82, 193-229.	2.4	125
45	Targeting the epithelial cells in fibrosis: a new concept for an old disease. Drug Discovery Today, 2013, 18, 582-591.	6.4	9
46	A Random Motility Assay Based on Image Correlation Spectroscopy. Biophysical Journal, 2013, 104, 2362-2372.	0.5	2
47	Epithelial Cells as Active Player In Fibrosis: Findings from an In Vitro Model. PLoS ONE, 2013, 8, e56575.	2.5	42
48	Patients with primary membranous nephropathy lack auto-antibodies against LDL receptor, the homologue of megalin in human glomeruli. CKJ: Clinical Kidney Journal, 2012, 5, 178-179.	2.9	4
49	From acute injury to chronic disease: pathophysiological hypothesis of an epithelial/mesenchymal crosstalk alteration in CKD. Nephrology Dialysis Transplantation, 2012, 27, iii43-iii50.	0.7	5
50	Recent Developments in Myofibroblast Biology. American Journal of Pathology, 2012, 180, 1340-1355.	3.8	1,043
51	Epithelial–mesenchymal crosstalk alteration in kidney fibrosis. Journal of Pathology, 2012, 228, 131-147.	4.5	47
52	Urinary Proteomics and Drug Discovery in Chronic Kidney Disease: A New Perspective. Journal of Proteome Research, 2011, 10, 126-132.	3.7	14
53	Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. Journal of Proteomics, 2011, 74, 2008-2017.	2.4	101
54	Renal fibrosis and proteomics: Current knowledge and still key open questions for proteomic investigation. Journal of Proteomics, 2011, 74, 1855-1870.	2.4	31

4

#	Article	IF	CITATIONS
55	The kidney as a target organ in pharmaceutical research. Drug Discovery Today, 2011, 16, 244-259.	6.4	3
56	Analysis of the oxido-redox status of plasma proteins. Technology advances for clinical applications. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 1338-1344.	2.3	8
57	In vivo characterization of renal autoâ€antigens involved in human autoâ€immune diseases: The case of membranous glomerulonephritis. Proteomics - Clinical Applications, 2011, 5, 90-97.	1.6	18
58	Autoimmunity in Membranous Nephropathy Targets Aldose Reductase and SOD2. Journal of the American Society of Nephrology: JASN, 2010, 21, 507-519.	6.1	190
59	Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer, 2009, 64, 244-246.	2.0	21
60	Stenting: Biomaterials in mini-invasive cardiovascular applications. Analytical and Bioanalytical Chemistry, 2005, 381, 531-533.	3.7	3
61	Comparison of primary mitral valve disease in German Shepherd dogs and in small breeds. Journal of Veterinary Cardiology, 2004, 6, 27-34.	0.9	83